Skip to content

Study · Not a test of the peptide alone · 2016

4 results

Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.

Ferrario MG, Lizán L, Montagnoli R, Ramírez de Arellano A

Primary care diabetes3 Nov 2015Cited by 4 (Europe PMC)

PMID26546244 (opens in a new tab)DOI10.1016/j.pcd.2015.10.002 (opens in a new tab)PepBankPUB-26546244
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01Computer modelNot a test of Liraglutide aloneIn silicoOther

    In adults with type 2 diabetes in Italy, a model with efficacy from RCTs gave a lower 26-week cost-per-controlled-patient with liraglutide (€1460) than with sitagliptin (€1820).

    In plain wordsIn a cost model for Italy, liraglutide cost less than sitagliptin for each patient who reached target at 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseCost-per-controlled-patient at 26 weeks (efficacy from RCT)
    Study

    n: not reported in source

    Cost-per-controlled-patient calculation using efficacy from RCTs and a meta-analysis
    Comparator
    Sitagliptin
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Cost-per-controlled-patient
    1460 €
    liraglutide, 26 weeks, RCT efficacy
    Cost-per-controlled-patient
    1820 €
    sitagliptin, 26 weeks, RCT efficacy

    Source sentences

    Summary
    Despite the higher acquisition cost of liraglutide vs. sitagliptin, at 26 weeks liraglutide resulted in a lower cost-per-controlled-patient (€1460 vs. €1820 - with efficacy from RCT - and €1593 vs. €2234 - with efficacy from a meta-analysis), as well as at 52 weeks (€2627 vs. €2649).
    1 context sentence
    Summary · context
    To estimate the short-term cost-per-controlled-patient with type 2 diabetes mellitus with liraglutide 1.2mg/day vs. sitagliptin 100mg/day as add-on treatment to metformin in Italy.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02Computer modelNot a test of Liraglutide aloneIn silicoOther

    In adults with type 2 diabetes in Italy, a model with efficacy from a meta-analysis gave a lower 26-week cost-per-controlled-patient with liraglutide (€1593) than with sitagliptin (€2234).

    In plain wordsIn a cost model for Italy, liraglutide cost less than sitagliptin for each patient who reached target at 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseCost-per-controlled-patient at 26 weeks (efficacy from meta-analysis)
    Study

    n: not reported in source

    Cost-per-controlled-patient calculation using efficacy from RCTs and a meta-analysis
    Comparator
    Sitagliptin
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Cost-per-controlled-patient
    1593 €
    liraglutide, 26 weeks, meta-analysis efficacy
    Cost-per-controlled-patient
    2234 €
    sitagliptin, 26 weeks, meta-analysis efficacy

    Source sentences

    Summary
    Despite the higher acquisition cost of liraglutide vs. sitagliptin, at 26 weeks liraglutide resulted in a lower cost-per-controlled-patient (€1460 vs. €1820 - with efficacy from RCT - and €1593 vs. €2234 - with efficacy from a meta-analysis), as well as at 52 weeks (€2627 vs. €2649).
    1 context sentence
    Summary · context
    To estimate the short-term cost-per-controlled-patient with type 2 diabetes mellitus with liraglutide 1.2mg/day vs. sitagliptin 100mg/day as add-on treatment to metformin in Italy.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03Computer modelNot a test of Liraglutide aloneIn silicoOther

    In adults with type 2 diabetes in Italy, the 52-week cost-per-controlled-patient was €2627 with liraglutide and €2649 with sitagliptin.

    In plain wordsIn a cost model for Italy, liraglutide and sitagliptin cost almost the same per patient who reached target at 52 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseCost-per-controlled-patient at 52 weeks
    Study

    n: not reported in source

    Cost-per-controlled-patient calculation using efficacy from RCTs and a meta-analysis
    Comparator
    Sitagliptin
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Cost-per-controlled-patient
    2627 €
    liraglutide, 52 weeks
    Cost-per-controlled-patient
    2649 €
    sitagliptin, 52 weeks

    Source sentences

    Summary
    Despite the higher acquisition cost of liraglutide vs. sitagliptin, at 26 weeks liraglutide resulted in a lower cost-per-controlled-patient (€1460 vs. €1820 - with efficacy from RCT - and €1593 vs. €2234 - with efficacy from a meta-analysis), as well as at 52 weeks (€2627 vs. €2649).
    1 context sentence
    Summary · context
    To estimate the short-term cost-per-controlled-patient with type 2 diabetes mellitus with liraglutide 1.2mg/day vs. sitagliptin 100mg/day as add-on treatment to metformin in Italy.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04Computer modelNot a test of Liraglutide aloneIn silicoOther

    In adults with type 2 diabetes in Italy, patients who switched from sitagliptin to liraglutide at 52 weeks had a lower 78-week cost-per-controlled-patient (€2889) than those continuing sitagliptin (€3970).

    In plain wordsIn a cost model for Italy, switching to liraglutide at 52 weeks cost less per patient at target than staying on sitagliptin.

    Peptide
    Liraglutide
    Outcome
    DecreaseCost-per-controlled-patient at 78 weeks after switching from sitagliptin
    Study

    n: not reported in source

    Cost-per-controlled-patient calculation using efficacy from RCTs and a meta-analysis
    Comparator
    Continuing sitagliptin
    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Cost-per-controlled-patient
    2889 €
    switch to liraglutide, 78 weeks
    Cost-per-controlled-patient
    3970 €
    continuing sitagliptin, 78 weeks

    Source sentences

    Summary
    At 78 weeks, in patients who have switched from sitagliptin to liraglutide at 52 weeks, the cost-per-controlled-patient is also lower than that of patients continuing sitagliptin for 78 weeks (€2889 vs. €3970).
    1 context sentence
    Summary · context
    To estimate the short-term cost-per-controlled-patient with type 2 diabetes mellitus with liraglutide 1.2mg/day vs. sitagliptin 100mg/day as add-on treatment to metformin in Italy.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.